home / stock / cslly / cslly quote
Last: | $94.29 |
---|---|
Change Percent: | -2.08% |
Open: | $95.83 |
Close: | $94.29 |
High: | $95.83 |
Low: | $91.79 |
Volume: | 22,690 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$94.29 | $95.83 | $94.29 | $95.83 | $91.79 | 22,690 | 03-28-2024 |
$93.88 | $95.711 | $93.88 | $95.711 | $93.37 | 34,522 | 03-27-2024 |
$92.31 | $95.02 | $92.31 | $95.02 | $90.6 | 50,028 | 03-26-2024 |
$92.37 | $92.9795 | $92.37 | $92.9795 | $92.37 | 31,832 | 03-25-2024 |
$91.48 | $91.68 | $91.48 | $93.9 | $91.45 | 20,270 | 03-22-2024 |
$90.68 | $91 | $90.68 | $91.169 | $90.68 | 20,452 | 03-21-2024 |
$91.99 | $91.8 | $91.99 | $92.13 | $90.62 | 27,247 | 03-20-2024 |
$91.06 | $91.225 | $91.06 | $91.98 | $90.51 | 28,201 | 03-19-2024 |
$91.43 | $91.65 | $91.43 | $92.3 | $91.43 | 18,658 | 03-18-2024 |
$91.55 | $91.82 | $91.55 | $91.9 | $91.5 | 25,703 | 03-15-2024 |
$92.29 | $95.2 | $92.29 | $95.2 | $92.12 | 32,992 | 03-14-2024 |
$93.01 | $95.08 | $93.01 | $95.08 | $90.99 | 25,838 | 03-13-2024 |
$93.03 | $95.18 | $93.03 | $95.18 | $92.2 | 23,170 | 03-12-2024 |
$92.684 | $89.6 | $92.684 | $92.97 | $89.6 | 27,279 | 03-11-2024 |
$94.24 | $95.6335 | $94.24 | $96.95 | $94.23 | 18,079 | 03-08-2024 |
$93.76 | $93.29 | $93.76 | $93.79 | $93 | 17,424 | 03-07-2024 |
$93.26 | $89.4 | $93.26 | $93.41 | $89.4 | 30,709 | 03-06-2024 |
$92.81 | $91.269 | $92.81 | $93.69 | $91.269 | 87,911 | 03-05-2024 |
$90.9 | $94.64 | $90.9 | $94.64 | $90.8 | 44,763 | 03-04-2024 |
$92.23 | $90.42 | $92.23 | $94.37 | $90.42 | 27,935 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure Canada NewsWire ST. GALLEN, SWITZERLAND , March 19, 2024 /CNW/ -- CSL Vifor today a...
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season PR Newswire SUMMIT, N.J. , March 6, 2024 /PRNewswire/ -- CSL Seqirus, a glob...
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is based on pivotal Phase 3 PROTECT Study results European Commission dec...